EMERGING AND RE-EMERGING INFECTIOUS

DISEASE PROGRAM

Description

In the recent past, the Philippines has seen many outbreaks of emerging
infectious diseases and it continues to be susceptible to the threat of re-
emerging infections such as leptospirosis, dengue, meningococcemia,
tuberculosis among. The current situation emphasizes the risks and
highlights the need to improve preparedness at local, national and
international levels for against future pandemics. New pathogens will
continue to emerge and spread across regions and will challenge public
health as never before signifying grim repercussions and health burden.
These may cause countless morbidities and mortalities, disrupting trade and
negatively affect the economy.

There are several social determinants contributing to the emergence of novel

infectious diseases and resurgence of controlled or eradicated infectious
diseases in our country. These contributing factors are namely: (1)
Demographic factors like the population distribution and density, (2)
international travel/ tourism and increased OFWs, (3) Socio-economic factors
and (4) Environmental factors. The latter includes our country’s vulnerability
to disasters, increased livestock production, man- made ecological changes
or industries and lastly the urbanization which encroach and destroy the
animal habitats.

Emerging and Re-emerging Infectious Diseases are unpredictable and create

a gap between planning and concrete action. To address this gap, there is a
need to come up with proactive systems that would ensure preparedness
and response in anticipation to negative consequences that may result in
pandemic proportions of diseases. Proactive and multi- disciplinary
preparedness must be in place to reduce the impact of the public the health
threats.

Vision

A health system that is resilient, capable to prevent, detect and respond to

the public health threats caused by emerging and re-emerging infectious
diseases

Mission
Provide and strengthen an integrated, responsive, and collaborative health
system on emerging and re-emerging infectious diseases towards a healthy
and bio-secure country.

Goal

Prevention and control of emerging and re-emerging infectious disease from

becoming public health problems, as indicated by EREID case fatality rate of
less than one percent

Program Strategies

The EREID Strategies are:

 Policy Development
 Resource Management and Mobilization
 Coordinated Networks of Facilities
 Building Health Human Resource Capacity
 Establishment of Logistics Management System
 Managing Information to Enhance Disease Surveillance
 Improving Risk Communication and Advocacy

Target Population/ Client

All ages; Citizen of the Philippines

Area of Coverage

Philippines and it’s international borders

Partner Institutions

DOH Central and Regional Bureau’s/Offices, Other Government and Non-

Government Offices, Medical Societies, Academe, Developmental Partners
(World Health Organization, FAO-OIE, CDC, GPP-Canada)

Policies and Laws

 Executive Order No. 168 - Creating the Inter-Agency Task

Force for the Management of Emerging Infectious Diseases in the
Philippines
 Administrative Order No. 10 s. 2011 - Creating the Philippine
Inter-Agency Committee on Zoonosis, Defining Its Powers, Functions,
Responsibilities, Other Related Matters and Providing Funds Thereof

Other Related Issuances/ Guidelines

  Administrative Order no. 2012-0022 - National Policy for the
Implementation of on International Health Regulation and Asia
Pacific Strategy for Emerging Diseases in the Philippines
 Department Memorandum No. 2017- 2558 - Creation of
Functional Groups for the National EREID Program
 Department Personnel Order No. 2005-1585 - Creation of a
Management Committee on Prevention and Control of Emerging and
Re-emerging Infectious Diseases (DOHMC-PCREID)
 Department Memorandum No. 2017 - 0348 - Interim Technical
Guidelines, Standards and other Instructions in the Implementation
of Enhanced Human Avian Flu Surveillance, Management, and
Infection Control in the Health Care Setting
 Department Memorandum No. 2016 - 0169 - Interim
Guidelines on the Clinical Management of Zika Virus Infection
 Department Memorandum No. 2014 - 0257 - Preparedness
and Response Plan for the Prevention and Control of Ebola Virus
Disease
 Department Memorandum No. 2014 - 0075 - Interim
Guidelines on the Preparedness and Response to MERS-CoV
 Department Memorandum No. 2009 - 0144 - Technical
Guidelines, Standards and other Instructions for Reference in the
Pandemic Response to Influenza A H1N1
 Department Memorandum No. 2009-0250 - Interim Guidelines
on the Prevention of Leptospirosis through the use of Prophylaxis in
Areas affected by Floods
 Department Memorandum No. 2005-0021 - Case Guidelines
on the Management and Control of Meningococcal Disease

Strategies, Actions Points

To achieve this goal within the medium term, with a benchmark of less than
one percent EREID case fatality rate, the EREID Program Strategic
Investment Plan highlights the seven Strategic Priorities, each with the
following goals:

1. Policy Development: Establish updated, relevant, and

implementable policies on EREID providing the overall direction in
implementing the different Program components for all the
network of health providers and facilities.
2. Resource Management and Mobilization: Effectively manage and
mobilize available resources from the DOH and partners both local
and international needed in EREID detection, preparedness, and
response.
3. Coordinated Networks of Facilities: Organize adequate and
efficient systems of coordination among network of facilities both
public and private needed in EREID detection, preparedness, and
 response within the context of integrated health service delivery
system at national and sub-national levels.
4. Building Health Human Resource Capacity: Health care
professionals skilled, competent and motivated in detection,
prevention and management of EREID cases, with provision of
supervised psychosocial support and risk communication at the
national and sub-national levels.
5. Establishment of Logistics Management System: Manage the
systems of procurement and distribution of logistics for EREID
detection, preparedness and response under each mode of
disease transmission.
6. Managing Information to Enhance Disease Surveillance: Improve
case detection and surveillance of EREID to prevent and or
minimize its entry and spread and to mitigate the possible impact
of widespread community and national transmission.
7. Improving Risk Communication and Advocacy: Institute a risk
communication and advocacy system that is factual, timely and
context relevant implemented at the national and sub-national
levels.

Program Accomplishments/ Status

Policy Development and Review:

 Zika Guidelines finalized and approved ; Avian Influenza Guidelines

updated
 Formation of the EREID Technical Working Group ; Experts Panel
and EREID Management Group
 Development of the Situational Analysis of EREID in the Philippines
 Development of the EREID Manual of Operations for Preparedness
and Response
 Development of the EREID 5- Year Strategic/ Investment Plan
 Active Participation in the finalization of the IRR of PhilCZ (AO No.
10)
 Community Simulation Exercise –CALABARZON (Oct 2017)
 Initial drafts of the Regional Preparedness and Response Plans
(18) ; Initial drafts of the provincial Preparedness and Response
plans (5) -CALABARZON

Resource Management and Mobilization:

 Program Implementation Review (PIR) (February 2017)

 Strategic Plan / Risk Communication Workshop (May 2017)
 Health Promotion / M&E Tool Workshop (Sept 2017)
 Participation in the Marawi Intervention
  Co-handling / assistance to BAI on the Avian Influenza (H5N6)
outbreak
 Funding/ Sub- allotments to all regional offices ; RITM and 5 SNLs
 Strengthened collaboration with DOH bureaus, government
agencies, medical societies, academe, civil organizations and
societies

Network of Facilities and Stakeholders:

 CBCP, Schools, AFP and LGU ; 7 TWG meetings conducted

 Medical societies as active (PIDSP, PISMD and PAFP)
 Academe collaboration started with UP Manila and NIH
 Philhealth, FAO and OIE, UP Manila, PGH as partners
 Regional EREID Forums : Region V, Region VI, Region IV A
 Field Visit : Region VI (RO, Hospital, RHU and LGU)

Logistic Management System:

 Procurement of PPE (Personal Protective Equipment); Doxycycline;

Oseltamivir;
 Pre-positioning EREID supplies to all regional offices (18) ; RITM and
Sub National Laboratories (SNLs)

Risk Communication and Advocacy:

 Risk Communication Guidelines (per mode of transmission) –May

2017
 IEC, media placements, FB, advisories on Zika, Leptospirosis, Avian
Influenza and JE
 Health Promotion Plan – Oct 2017

Calendar of Activities

WAYS FORWARD – 2018

 Consolidation of all Regional preparedness plans and assistance to

advocate to their Regional Directors and LCEs
 Strengthening of the Rapid Response Team (RRT) – Regional,
Provincial and LGU levels
 Strengthened collaboration with HEMB, HPCS, EB, RITM and other
partner DOH bureaus and private institutions
 Institutionalize the ONE HEALTH Paradigm (animal, human and
environmental health) in the EREID operational framework and
activities
  Integration of strategies addressing the emerging infectious
diseases and the public health emergencies as in APSED III 2017
proposal
 IHR Joint External Evaluation Tool (JEE)
 Development of EREID National Policy and Program Monitoring Tool
 MOP dissemination thru Training Modules / Capacity Enhancement
(18 ROs)
 One Health Strategy Workshops
 Interim Clinical Guidelines/ Policies - Review and Updating
 Field Support Visits / Annual Partners’ / Stakeholders’ Forum

Statistics

Zika: Case Fatality Rate: Zero (0) (2017)

AH5N6: No Human cases (2017)

Program Manager Contact Number

DR. GEMMA ARELLANO

Program Manager
Email add: ereidprogram.dohco@gmail.com
Trunkline: 651-7800 loc. 2354

https://www.doh.gov.ph/emerging-and-re-emerging-infectious-disease-program

Infectious Diseases
1. Acute Respiratory Infection
2. Influenza A (H1N1)
3. Bird Flu (Avian Influenza)
4. Chickenpox
5. Cholera
 6. Dengue
7. Diarrhea
8. Diphtheria
9. Ebola
10.Hand, Foot, and Mouth Disease
11.Hepatitis A
12.Hepatitis B
13.Hepatitis C
14.HIV/AIDS
15.Influenza
16.Leprosy
17. Malaria
18.Measles
19.Meningococcemia
20. Pertussis
21. Poliomyelitis
22. Rabies
23. Severe Acute Respiratory Syndrome (SARS)
24. Sore Eyes
25. Tuberculosis
26. Typhoid Fever

http://caro.doh.gov.ph/?page_id=383

DENGUE

BACKGROUND

Dengue is the fastest spreading vector-borne disease in the world endemic in 100 countries·

 Dengue virus has four serotypes (DENV1, DENV2, DENV3 and DENV4)

 First infection with one of the four serotypes usually is non-severe or asymptomatic, while
second infection with one of other serotypes may cause severe dengue.

 Dengue has no treatment but the disease can be early managed.

 The five year average cases of dengue is 185,008; five year average deaths is 732; and five
year average Case Fatality Rate is 0.39 (2012-2016 data).

TRANSMISSION

Dengue virus is transmitted by day biting Aedes aegypti and Aedes albopictus mosquitoes.

DENGUE CASE CLASSIFICATION AND LEVEL OF SEVERITY

  Dengue illness is categorized according to level of severity as dengue without warning signs,
dengue with warning signs and severe dengue.

 Dengue without warning warnings can be further classified according to signs and symptoms
and laboratory tests as suspect dengue, probable dengue and confirmed dengue.

a. dengue without warning signs

a.1 suspect dengue

- a previously well individual with acute febrile illness of 1-7 days duration
plus two of the following: headache, body malaise, retro-orbital pain, myalgia,
arthralgia, anorexia, nausea, vomiting, diarrhea, flushed skin, rash (petechial,
Hermann’s sign)

a.2 probable dengue

- a suspect dengue case plus laboratory test: Dengue NS1 antigen test and atleast
CBC (leukopenia with or without thrombocytopenia) or dengue IgM antibody test
(optional)

a.3 confirmed dengue

- a suspect or probable dengue case with positive result of viral

culture and/or Polymerase Chain Reaction (PCR) and/or Nucleic Acid Amplification
Test- Loop Mediated Amplification Assay (NAAT-LAMP) and/ or Plaque Reduction
Neutralization Test (PRNT)

b. dengue with warning signs

• a previously well person with acute febrile illness of 1-7 days plus any of the following:
abdominial pain or tenderness, persistent vomiting, clinical signs of fluid accumulation
(ascites), mucosal bleeding, lethargy or restlessness, liver enlargement, increase in
haematocrit and/or decreasing platelet count

c. severe dengue

severe plasma leakage leading to

 shock (DSS)

 fluid accumulation with respiratory distress

severe bleeding

 as evaluated by clinician

severe organ impairment

  Liver: AST or ALT ≥ 1000
 CNS: e.g. seizures, impaired consciousness
 Heart:and other organs (i.e. myocarditis, renal failure)

PHASES OF DENGUE INFECTION

a. Febrile Phase
 Usually last 2-7 days
 Mild haemorrhagic manifestations like petechiae and mucosal membrane bleeding (e.g
nose and gums) may be seen.
 Monitoring of warning signs is crucial to recognize its progression to critical phase.
b. Critical Phase
 Phase when patient can either improve or deteriorate.
 Defervescence occurs between 3 to 7 days of illness. Defervescence is
known as the period in which the body temperature (fever) drops to almost
normal (between 37.5 to 38°C).
 Those who will improve after defervescence will be categorized as Dengue
without Warning Signs, while those who will deteriorate will manifest warning
signs and will be categorized as Dengue with Warning Signs or some may
progress to Severe Dengue.
 When warning signs occurs, severe dengue may follow near the time of
defervescence which usually happens between 24 to 48 hours.
c. Recovery Phase
 Happens in the next 48 to 72 hours in which the body fluids go
back to normal.
 Patients’ general well-being improves.
 Some patients may have classical rash of “isles of white in the sea of
red”.
 The White Blood Cell (WBC) usually starts to rise soon after
defervescence but the normalization of platelet counts typically
happens later than that of WBC.

MANAGEMENT (based on patient type)

1. Group A- patients who may be sent home

These are patients who are able to:

 Tolerate adequate volumes of oral fluids

 Pass urine every 6 hours
 Do not have any of the warning signs particularly when the fever subsides
 Have stable haematocrit
2. Group B- patient who should be referred for in-hospital management

Patients shall be referred immediately to in-hospital management if they have the following
conditions:
  Warning signs\
 Without warning signs but with co-existing conditions that may make dengue
or its management more complicated ( such as pregnancy, infancy, old age,
obesity, diabetes mellitus, hypertension, heart failure, renal failure, chronic
haemolytic diseases such as sickle- cell disease and autoimmune diseases,
etc.)
 Social circumstances such as living alone or living far from health facility or
without a reliable means of transportation.
 The referring facility has no capability to manage dengue with warning signs
and/or severe dengue.
3. Group C- patient with severe dengue.requiring emergency treatment and
urgent referral

These are patients with severe dengue who require emergency treatment
and urgent referral because they are in the critical phase of the disease and
have the following:

 Severe plasma leakage leading to dengue shock and/or fluid

accumulation with respiratory distress;
 Severe haemorrhages;
 Severe organ impairment (hepatic damage, renal impairment,
cardiomyopathy, encephalopathy or encephalitis)

Patients in Group C shall be immediately referred and admitted in the hospital within 24
hours.

LABORATORY TESTS

Test Description
 Requested between 1-5 days of illness
 Use to detect dengue virus antigen during
early phase of acute dengue infection
1. Dengue NS1 RDT
 Test is for free in all health centers and
selected public hospitals nationwide
 Requested beyond five days of illness
 Use to detect dengue antibodies during
acute late stage of dengue infection (IgM)
and to determine previous infection (IgG)
 May give false positive result due to
2. Dengue IgM/IgG antibodies induced by dengue vaccine
 May cross react with other arboviral diseases
such as Chikungunya and Zika
 DOH augmentation is limited to selected
government hospitals only
 One of the gold standard laboratory tests to
confirm dengue virus.
 Molecular based test confirmatory test
3. Polymerase Chain Reaction (PCR)
 Available only in dengue sub-national and
national reference laboratories
  A novel molecular-based confirmatory test
used to detect dengue virus.
 Work just like PCR but cheaper and simpler
4. Nucleic Acid Amplification Test- in nature.
Loop Mediated Isothermal Amplification
Assay (NAAT-LAMP)  In the pipeline to be introduced under the
National Dengue Prevention and Control
Program in district and provincial hospitals
 Gold standard to characterize and quantify
circulating level of anti-DENV neutralizing
5. Plaque Reduction Neutralization antibody (NAb)
Test (PRNT)  Available only at the dengue national
reference laboratory
6. Other tests:
 Routinely used in hospitals as standard
-Total While Blood Cell (WBC) count dengue diagnostic tests
 Look for trend of decreasing WBC,
-Platelet decreasing platelet and increasing
hematocrit
-Hematocrit

NATIONAL DENGUE PREVENTION AND CONTROL PROGRAM

Vision A dengue free Philippines

Mission Ensure healthy lives and promote well-being for all at all
ages

Goal To reduce the burden of dengue disease

Objectives/ 1.) To reduce dengue morbidity by atleast 25% by 2022

Indicators Morbidity rate = No. of suspect, probable & confirmed

cases x100,000

total population

(baseline: 198.1 per 100,000

population)

(2015 data: 200,145/100,981,437 x

100,000)

2.) To reduce dengue mortality by atleaset 50% by 2022

 Mortality rate = No of dengue (probable & confirmed)
deaths x 100,000

total population

(baseline: 0.59 per 100,000

population)

(2015 data: 598/100,981.437 x

100,100)

3.) To maintain Case Fatality Rate (CFR) to < 1% every

year.

CFR = no. of dengue (probable & confirmed)

deaths x 100

no. of probable & confirmed cases

PROGRAM COMPONENTS

1. Surveillance
 Case Surveillance through Philippine Integrated Disease
Surveillance and Response (PIDSR)
 Laboratory-based surveillance/ virus surveillance through
Research Institute for Tropical Medicine (RITM) Department of
Virology, as national reference laboratory, and sub-national
reference laboratories.
 Vector Surveillance through DOH Regional Offices and RITM
Department of Entomology

2. Case Management and Diagnosis

 Dengue Clinical Management Guidelines training for hospitals.

 Dengue NS1 RDT as forefont diagnosis at the h ealth center/ RHU
level.
 PCR as dengue confirmatory test available at the sub-national
and national reference laboratories.
 NAAT-LAMP as one of confirmatory tests will be available at
district hospitals, provincial hospitals and DOH retained hospitals.

3. Integrated Vector Management (IVM)

  Training on Vector Management, Training on Basic Entomology
for Sanitary Inspector, Training on Integrated Vector Management
(IVM) for health workers.
 Insecticide Treated Screens (ITS) as dengue control strategy in
schools.

4. Outbreak Response

 Continuous DOH augmentation of insectides such as adulticides

and larvicides to LGUs for outbreak response.

5. Health Promotion and Advocacy

 Celebration of ASEAN Dengue Day every June 15

 Quad media advertisement
 IEC materials

6. Research

STRATEGIES

 Enhanced 4S Strategy

S - earch and Destroy

S - eek Early Consultation

S - elf Protection Measures

S - ay yes to fogging only during outbreaks

LINKS TO PROGRAM POLICIES AND GUIDELINES

AO 2016-0043
Guidelines for the nationwide Implementation of Dengue Rapid Diagnostic Test

AO 2012-006
Revised Dengue Clinical Management Guidelines

AO 2001-0045 Guidelines on the Application of Larvicides on the Breeding Sites of Dengue Vector Mosquitoes in Domestic W

DM 2017-0353 Implementation Guidelines for Initial Implementation of Nucleic Acid Amplification Assay - Loop Mediated Iso
 (LAMP) as One of Dengue Confirmatory Tests to Support Dengue NSI RDT

DM 2015-0309 Reactivation of Dengue Fast Lanes and Continuing Improvement of Systems for Dengue Case Management an

Technical Guidelines, Standards and other Instructions for Reference in the Implementation of Sentinel-based
DM 2014-0112
Surveillance

https://www.doh.gov.ph/Health-Advisory/Dengue

Evalyn A. Roxas, MD
Assistant Professor

Department of Medical Microbiology

Dr. Evalyn A. Roxas is a graduate of Bachelor of Science in Biology, magna cum laude from
the Pamantasan ng Lungsod ng Maynila (PLM). She then pursued studying in the same
university and graduated with the degree of Doctor of Medicine finishing rank 6 of her class.
After this, she continued her medical profession and had residency training in Internal
Medicine from Ospital ng Maynila Medical Center. She further subspecialize in Infectious
Diseases and completed her fellowship training in the said program from the University of
the Philippines-Philippine General Hospital (UP-PGH). She is now a diplomate and fellow
both of the Philippine College of Physicians (PCP) and Philippine Society for Microbiology and
Infectious Diseases (PSMID).

Her interest in microbiology and infectious diseases brought her at the Department of
Medical Microbiology. She is now the newest addition to the distinguished roster of faculty of
the Department with a rank of Assistant Professor V. She teaches BS Public Health
undergraduate students and also dentistry, nursing and medical students.

Some of her interests even when she was still a fellow were on leptospirosis and HIV where
she was able to publish papers entitled “Clinical Profile of Patients Diagnosed with
Leptospirosis After a Typhoon” and “A Case Report on Invasive Trichosponosis in an AIDS
Patient”. She had short course training also on leptospirosis at the Department of
Bacteriology of Kyushu University in Fukuoka, Japan.

Currently her research interests are still on leptospirosis , HIV, TB, and infection control.
She continuously hones and improves her potential as an academician as she is presently
enrolled at the graduate school of the College of Public Health taking up Master of Public
Health.

Contact:

5260811
Publications
 Lopez SM, Ramiro VR, and Roxas EA. Measuring Stigma and Discrimination
towards People Living with HIV among Health Care Workers in a Tertiary, Government
Teaching Hospital in the Philippines. Acta Medica Philippina. (2017); 51 (4); 319-326
 Salvana EMT, Roxas EA, Penamora MG. Immunocompromised Hosts and Parasitic
Infections. Chapter 8: Special Topics in Parasitology.In Vicente Y. Belizario Jr. and
Winifreda U de Leon (eds). Medical Parasitology in the Philippines.. University of the
Philippines Press 2015. (Chapter in a Book). (2015); ;
 Gloriani NG, Cavinta LC, Roxas EA, Villanueva SYAM. Prevention and Control of
Leptospirosis in the Philippines: A Manual for Health Workers.. DOST-PCHRD. (2015); ;
 Mendoza M, Roxas E, et al.. Clinical Profile of Patients Diagnosed with
Leptospirosis After a Typhoon: A Multicenter Study.. Southeast Asian J Trop Med Public
Health . (2013). (2013); 44 (6); 1021-1035
 Mendoza M, Roxas E, et al. Clinical Profile of Patients Diagnosed with Leptospirosis
After a Typhoon: A Multicenter Study. Southeast Asian J Trop Med Public Health .
(2013); 44 (6); 1021-1035
 Roman D, Salvana E, Penamora M, Roxas E, Leyritana K, and Saniel M..
Invasive Trichosporonosis in an AIDS Patient: Case Report and Review of the Literature..
International Journal Of STD and AIDS. July 2013.. ; ;
 Roman D, Salvana E, Penamora M, Roxas E, Leyritana K, and Saniel M..
Trichosponosis in an AIDS Patient: Case Report and Review of the Literature.
International Journal of STD and AIDS. ; ;
http://cph.upm.edu.ph/user-profile/117

WHO/Chris Black

Infectious diseases are caused by pathogenic microorganisms, such as bacteria,

viruses, parasites or fungi; the diseases can be spread, directly or indirectly, from
one person to another. Zoonotic diseases are infectious diseases of animals that can
cause disease when transmitted to humans.

http://www.who.int/topics/infectious_diseases/en/

WORLD HEALTH ORG.

DOCTORS OF INFECTIOUS DISEASES

Raquel Victoria M.
Ecarma, M.D.
Section Head Chair,
Infection Control
Committee
University of the East Ramon Magsaysay
Medical School:
Memorial Medical Center (UERMMMC)
National Kidney and Transplant Institute
Residency:
Department of Internal Medicine
UP- Philippine General Hospital(Infectious
Fellowship:
Diseases)
Infectious Disease,Internal Medicine
Specialization: Transplant InfectionsHIV/AIDS Infection
Control

Rosanna A. Ditangco, M.D.

Far Eastern University-Nicanor ReyesMedical
Medical School:
Foundation, Institute of Medicine
National Kidney and Transplant Institute(Internal
Residency:
Medicine)
U P-Philippine General Hospital(Infectious
Fellowship:
Diseases)
Specialization: Internal MedicineInfectious Diseases

Myrna T. Mendoza, M.D.

University of the East Ramon Magsaysay
Medical School:
Memorial Medical Center (UERMMMC)
Residency: Mary Johnston Hospital
Fellowship: UP-Philippine General Hospital
Infectious Diseases in Immuno Compromised
Specialization:
Patients Infection Control
RIZAL MEDICAL CENTER is a DOH-retained teaching and training
hospital with 300-bed capacity. We boast of a wide variety of medical
specialty services from minimally invasive surgery and endoscopy,
comprehensive maternal and child health care, laboratory and
radiologic facilities, multi-specialty cancer care to nuclear medicine
and physical therapy. Our line-up of medical specialists includes
pioneers and leaders in specialty societies.

We have been honored with the Philhealth award of excellence and the
gold awardee for malinis, mabango na ospital by the Department of
Health.

We would like to invite all of you to experience affordable, quality and

safe care provided by our warm and compassionate staff. We hope that
you will consider RMC as your hospital of choice.

FIGHT AGAINST DENGUE

Last March 6, 2018, Asec. Dr. Maria Francia M. Laxamana of the
Department of Health had a surprise visit to the Emergency Room of
Rizal Med to check on the Dengue Fast Lane provided by the hospital
for our patients. The Dengue Fast Lane was staffed by one of our
passionate and dedicated nurses in the person of Ms. Marga Mae
Mariano. Ms. Mariano was trained to care for pediatric patients and is
certified in infectious disease nursing by the Department of health. Dr.
Laxama was ushered by Dr. Buddy Ortego (Chief Administrative Officer)
and Dr. Louise Marie Flores (Chief Nursing Officer) throughout the visit.

http://rmc.doh.gov.ph/training